http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오우용(Woo Yong Oh),이상호(Sang Ho Lee),주상섭(Sang Sup Jew),박형근(Hyeung Geun Park),함광수(Kwang Su Ham),조장섭(Jang Sup Cho),이선미(Sun Mee Lee) 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A General pharmacological properties of (R)-JG-381 were examined in laboratory animals to investigate its safety profile. Administration of (R)-JG-381 (50 and 100 mg/kg) in mice and rats had no effects of general behaviors, central nervous system of the animals in test systems of pentobarbital-induced sleeping time, writhing syndromes induced by 0.7% acetic acid, chemo-shock produced by pentylenetetrazole, and, however, had mild effects on motor coordination. Heart rate and blood pressure were not changed by (R)-JG381 treatment. (R)-JG-381 also showed mild effects on intestinal propulsion and gastric secretion. These results suggest that (R)-JG-381 dose not exert serious pharmacological effects.
오우용(Woo Yong Oh),주상섭(Sang Sup Jew),박형근(Hyeung Geun Park),함광수(Kwang Su Ham),조장섭(Jang Sup Cho),이선미(Sun Mee Lee) 한국응용약물학회 2000 Biomolecules & Therapeutics(구 응용약물학회지) Vol.8 No.3
(R)-JG-381, a R form of alkylglycidic acid derivative, was examined for mutagenicity in the reverse mutation test on bacteria, chromosomal aberration test on cultured mammalian cells and micronucleus test in mice. In the reverse mutation test on bacteria using Salmonella typhimurium strain TA98, TA100, TA102, TA1535, TA1537 with or without a metabolic activation system (S9 mix), (R)-JG-381 did not affect the revertant colonies but significantly increased revertant colonies in one test strain, TA98, compared with the vehicle control. In the chromosomal aberration (CA) test using cultured Chinese Hamster Lung fibroblast(CHL) cells, the number of aberrant cells was not increased in the presence or absence of S9 mix at concentration of the (R)-JG-381 0.025㎕/㎖ to 0.1 ㎕/㎖, compared with vehicle control. In the micronucleus (MN) test, micronucleated polychromatic erythrocytes in the (R)-JG-381-treated mice were not different from those of the vehicle-treated mice.
Nalbuphie의 병용투여에 의한 morphine의 내성 및 의존성 헝성 저하효과
정면우(Myeon Won Chung),임화경(Hwa Kyung Lim),전용준(Yong Joon Jeon),김혜정(Hye Jung Kim),박인숙(In Sook Park),오우용(Woo Yong Oh),왕소영(So Young Wang),박윤주(Yoonju Park),강주희(Ju Hee Kang),김동섭(Dong Sup Kim),김주일(Joo Il Kim) 대한약학회 2002 약학회지 Vol.46 No.4
Morphine has been used widely on the treatment of many types of chronic pain. However the development of tolerance to morphine by repeat application is a major problem in pain therapy: The purpose of the present study was to investigate whether combined administration of nalbuphine with morphine affects the development of tolerance to and dependence on morphine. We hypothesize that the use of nalbuphine, k-agonist may prove to be useful adjunct therapy to prevent morphine-induced undesirable effects in the management of some forms of chronic pain. Morphine (10 mg/kg) was injected to rats intraperitoneally for 5 days. The variable dose of nalbuphine (0.1,1.0 and 5.0 mg/kg) was administered (I.p.) in combination with morphine injection. The development of tolerance to morphine was assessed by measuring the antinociceptive effect with the Randall-Selitto apparatus. The development of dependence on morphine was determined by the scoring the precipitated withdrawal signs for 20 min after injection of naloxone (10 mg/kg,I.p.). Nalbuphine did not attenuate antinociceptive effect of mofhine in rats. Interesting1y; combined administration of morphine with nalbuphine (100:1) sign- nifcantly attenuated the development of morphine tolerance and dependence. These results suggest that the co-admin-istration of nalbuphine with morphine in chronic morphine treatment can be one of therapies to reduce the development of dependence on morphine.
신약개발을 위한 바이오이미징 기술의 동향 파악 및 발전 방안
이종구(Jong Gu Lee),김승희(Seung Hee Kim),김정곤(Jeong Kon Kim),김경원(Kyung Won Kim),조우리(Woo Ri Jo),유선애(Sun Ae Ryu),박지원(Zewon Park),이정연(Jung-Yeon Yi),김보라(Bora Kim),오우용(Woo Yong Oh) 대한약학회 2018 약학회지 Vol.62 No.4
With change of medical paradigm toward patient-focused and personalized medication, the focus has changed from treatment of diseases to prevention of diseases. Owing to the increase in chronic diseases and population aging, the Korean pharmaceutical market size has rapidly increased, making the pharmaceutical industry the next-generation strategic sector. However, when considering the scale of investments, has indicated very low success rate. In addition, it took very long time to develop a new drug, leading to such undesirable outcomes (approval of small number of new drugs and decreased productivity, compared to R&D investment). Therefore, the need for development of new drug development strategies and introduction of new concept to increase the efficiency of the new drug development and to reduce the devel-opment cost has been highlighted. Accordingly, it is necessary to assure paradigm shift and coherent linking of pre-clinical and clinical studies, in order to correctly select candidate drugs for clinical studies. In order to overcome limitations of clin-ical studies, developed countries have expanded supports and investments in development of techniques for clinical eval-uation and improvement of clinical program. Techniques obtained from such activities will be primarily used in establishing regulatory requirements as well as international standards. One of such alternative techniques for clinical evaluations is “bioimaging technique”. The bioimaging technique is a non-invasive technique to show living organism s structural and functional images. It can visualize normal biological processes, pathological processes and pharmacological responses to treatments and enable objective measurement and evaluation. It includes X-ray, CT, MRI, PET and others widely used in medical examinations. In this study, the bioimaging technique and its utilization are carefully investigated and regulatory trends in foreign countries are analyzed to identify current status in Korea. In addition, suggestions have provided to activate research of bioimaging technique in Korea and improve the system for review and evaluation of medicinal products.
의약품의 효능별 안전성·유효성 평가에 관한 조사연구(Ⅰ) : 항균제 Antiboiotics
박윤주,최기환,김동섭,박인숙,정면우,임화경,오우용,강주희,박찬웅,김주일 식품의약품안전청 2001 식품의약품안전청 연보 Vol.5 No.-
새로운 물질이 개발되어 신약으로 탄생하기까지 많은 시간과 노력, 예산이 필요하다. 최근, 우리 나라에서도, 신약캐발이 어릴고 힘든 분야이지만 새로운 신약개발을 총해 얻어지는 분가가치가 막대함을 인식, 연구에 박차를 가하 있는 실정이다. 본 연구는, 의약품 개발 선진국인 미국 FDA에서 발행하는 참고자료 중 항균제 임상편가에 대한 가이드라인 및 주요 임상적응증별 항균제 기발(지역사획회득성 폐렴, 원내감염성 계렴, 급성기관지염의 2차세균감염, 만성기지염의 급성세균성 악화, 연쇄구균에 의한 인두영 및 편도염 , 단순성 요로감염증, 복합성 요로감염증 및 신우신영, 급성 세균성 부비동옆, 항 바이러스제 개발시 전임상단계에서 고려사항, 항 바이러스제 허가와 된련 잉상적 고려사항, 카레타 괸련 혈류감염)에 있어서의 파이드라인 등의 자료를 소개함으로져, 향후 제약사의 항균제 신약개발 및 허가 신청된 의악품의 전임상차료 및 잉상시험자료의 검토 평가업무에 참고자료로 활용될 수 있을 것이다. Changing or unclear interpretations of clinical trial data needed to demonstrate the effectiveness and safety of antimicrobial drug products have a times led to confusion and frustration on the part of both applicants and division of these drug products reviewers. The FDA published guidance on desing clinical protocols, implementing, and analyzing data from clinical trials for antimicrobial drug products has been presented and additional companion guidances introduced specific issues to individual infections. This document provides applicants and reviewers with minimal information appropriate for the clinical development of routine antimicrobial drug products and identifies issues common to many antimicrobial drug applications. The agency can use the kind of information to determine whether the antimicrobial drug product under study is safe and effective in the treatment of the specific infection studied.